Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

NEWYORKSILVERKING Sep. 13 at 4:45 PM

$VYNE 8k out after bell Friday..Notes possible r/s next March d/t sub dollar..Can apply for additional extension beyond that also..Notes that they are "considering all options to regain compliance"...

1 · Reply

nonamestockz Sep. 13 at 10:02 AM

$VYNE step by step

0 · Reply

Messerschmittbf109 Sep. 12 at 10:57 PM

$VYNE nothing normal red .. flat around 0,3 no verve

0 · Reply

Kawatani892007 Sep. 12 at 9:03 PM

$SLXN Show you some facts about its CFO. Mirit Horenshtein Hadar, CPA Chief Financial Officer Over 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech industries. CFO Gouzy Israel (Nasdaq: “GAUZ”). V.P. Finance Foamix Pharmaceuticals Inc. (currently Nasdaq“VYNE”) Look at the chart of $VYNE. She is NOT qualified. The board should know it.

1 · Reply

revueltoL Sep. 12 at 8:39 PM

$VYNE what’s coming?

0 · Reply

Tonyboner Sep. 12 at 7:15 PM

$VYNE Any news on partner on bet inhibitor will drive this crazy, it's a sit and hold, waiting will pay off, was in the $8 range in May, will look to add on weakness.

2 · Reply

Tonyboner Sep. 12 at 5:37 PM

$VYNE Break up value, here is around 70c, still has pipeline. Long @31c

0 · Reply

BadAssBillyGun Sep. 12 at 2:54 PM

$VYNE

3 · Reply

bochico Sep. 12 at 12:11 PM

$VYNE can we keep moving up? $VYNE 🚀💰

0 · Reply

nightstocker15 Sep. 11 at 7:34 PM

$VYNE spike this SOB into the close! Drop that PR!

0 · Reply

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Jul 30, 2025, 8:00 AM EDT - 6 weeks ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 2 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 4 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 5 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 5 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 6 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 6 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 7 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 7 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 8 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 9 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 1 year ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 1 year ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Dec 2, 2022, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

NEWYORKSILVERKING Sep. 13 at 4:45 PM

1 · Reply

nonamestockz Sep. 13 at 10:02 AM

$VYNE step by step

0 · Reply

Messerschmittbf109 Sep. 12 at 10:57 PM

$VYNE nothing normal red .. flat around 0,3 no verve

0 · Reply

Kawatani892007 Sep. 12 at 9:03 PM

1 · Reply

revueltoL Sep. 12 at 8:39 PM

$VYNE what’s coming?

0 · Reply

Tonyboner Sep. 12 at 7:15 PM

$VYNE Any news on partner on bet inhibitor will drive this crazy, it's a sit and hold, waiting will pay off, was in the $8 range in May, will look to add on weakness.

2 · Reply

Tonyboner Sep. 12 at 5:37 PM

$VYNE Break up value, here is around 70c, still has pipeline. Long @31c

0 · Reply

BadAssBillyGun Sep. 12 at 2:54 PM

$VYNE

3 · Reply

bochico Sep. 12 at 12:11 PM

$VYNE can we keep moving up? $VYNE 🚀💰

0 · Reply

nightstocker15 Sep. 11 at 7:34 PM

$VYNE spike this SOB into the close! Drop that PR!

0 · Reply

BadAssBillyGun Sep. 11 at 6:06 PM

$VYNE nice swing in $VNCE and topped up my long position here with the profits Liking this one for a multi day runner .

0 · Reply

Quixote_Don Sep. 11 at 5:46 PM

$VYNE Hoping the price stays at this level and they will not announce shop closure until early next week. Waiting for the funds to settle so that I can grab some more!

0 · Reply

revueltoL Sep. 11 at 4:32 PM

$VYNE I’m getting excited now …getting into that “pump it up” territory 🤣

1 · Reply

nonamestockz Sep. 11 at 3:41 PM

$VYNE above .33 we will see .72

2 · Reply

Duskfall Sep. 11 at 2:57 PM

$GLMD $GLMD Here's a bit of DD 📋🖋️ 1. AM-001 Study Aramchol Meglumine Suspension 400 mg achieved approximately double the AUC (exposure) compared to the older Aramchol acid tablet version. This AM-001 study is expected to be completed in the 🚨second half of 2025! 2. Oncological studies A Phase 1b study for the Regorafenib + Aramchol combination is planned for 🚨Q4 2025. More DD coming at some point.. It's rare that I post these. Usually I don't😴 I also like these setups👇 $TNFA $MYNZ $INTS $VYNE

0 · Reply

nonamestockz Sep. 11 at 2:42 PM

$VYNE rocket today?

0 · Reply

DarvasBoxing Sep. 11 at 2:38 PM

$VYNE .03. I know it’s small but nice to see

2 · Reply

nightstocker15 Sep. 11 at 2:33 PM

$VYNE this is just the appetizer! Main course coming 🙌💪

1 · Reply

CashtyNashty Sep. 11 at 2:06 PM

$VYNE looks like the tides are turning. Believe in what’s right!

1 · Reply

AlwaysLearning72 Sep. 11 at 2:40 AM

$VYNE hopefully today is the start of a nice uptrend.

1 · Reply

NEWYORKSILVERKING Sep. 10 at 6:52 PM

$VYNE Poor loser still waiting 1 year later.. bcbholdem Jun 12, 2024 10:19 AM $VYNE When is the next reverse-split?

2 · Reply

nonamestockz Sep. 10 at 6:49 PM

$VYNE Open your eyes - next $WLDS

0 · Reply

Market Cap	8.04M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	1,213,800
Avg Vol	2,432,106
Day's Range	N/A - N/A
Shares Out	25.47M
Stochastic %K	61%
Beta	1.80
Analysts	Sell
Price Target	$2.00